Dyne Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Dyne Therapeutics reports significant clinical progress for DMD and DM1 programs, secures substantial financing, and expands its pipeline for genetically driven neuromuscular diseases.
NASDAQ
10-K: Dyne Therapeutics Reports Progress in Neuromuscular Disease Programs, Faces Financial Challenges
Dyne Therapeutics, a clinical-stage company, is advancing its pipeline of neuromuscular disease therapeutics, but continues to incur significant losses and requires substantial additional funding.
NASDAQ
Dyne Therapeutics' 10-K filing details the company's financial status and progress in developing treatments for muscle diseases, including positive initial clinical data for its DM1 and DMD programs.